About Anu Osinusi

Anu serves as Vice President, Clinical Development where she is responsible for overseeing the Viral Hepatitis (Hep B, C and D), Respiratory and Emerging (COVID-19, Ebola, RSV and others) Viruses portfolio at Gilead Sciences, Inc. Anu is a clinician-researcher with over 15 years of experience in drug development, infectious diseases, liver diseases and global health and .

Since joining Gilead after a successful academic career, Anu has led several cross-functional teams advancing multiple compounds from pre-clinical through early, mid and late stage development to global approvals including several Hepatitis C therapies and more recently Remdesivir, the first approved therapeutic for COVID-19.

She is the author of over 80 scientific publications and has a passion for rapidly advancing therapeutics while building high performing teams